Integra LifeSciences (NASDAQ:IART) Stock Price Down 4.1% - What's Next?

Key Points

• Integra LifeSciences stock fell by 4.1% to close at $14.12, with trading volume notably down by 96% from its average.
• The company reported $0.45 earnings per share for the last quarter, surpassing analysts' expectations, but revenue fell by 0.6% year-over-year.
• Institutional investors hold approximately 84.78% of Integra LifeSciences' shares, with significant recent increases in holdings from various firms.

Integra LifeSciences Holdings Corporation (NASDAQ:IART - Get Free Report) dropped 4.1% during mid-day trading on Thursday . The company traded as low as $14.43 and last traded at $14.12. Approximately 38,810 shares changed hands during mid-day trading, a decline of 96% from the average daily volume of 1,053,241 shares. The stock had previously closed at $14.73.

Integra LifeSciences Stock Down 4.6%

The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.73 and a current ratio of 1.23. The stock has a market cap of $1.10 billion, a P/E ratio of -2.16 and a beta of 1.21. The stock's fifty day simple moving average is $14.13 and its 200-day simple moving average is $14.78.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.43 by $0.02. The firm had revenue of $415.61 million during the quarter, compared to the consensus estimate of $395.06 million. Integra LifeSciences had a negative net margin of 30.87% and a positive return on equity of 12.15%. The business's revenue for the quarter was down .6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.63 EPS. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. As a group, research analysts forecast that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current fiscal year.

Institutional Trading of Integra LifeSciences

Institutional investors have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Integra LifeSciences by 205.9% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 3,132 shares of the life sciences company's stock worth $38,000 after acquiring an additional 2,108 shares during the period. Osaic Holdings Inc. lifted its holdings in shares of Integra LifeSciences by 36.6% during the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company's stock worth $51,000 after acquiring an additional 1,104 shares during the period. AlphaQuest LLC bought a new stake in shares of Integra LifeSciences during the 2nd quarter worth approximately $73,000. EMC Capital Management bought a new stake in shares of Integra LifeSciences during the 2nd quarter worth approximately $75,000. Finally, CWM LLC lifted its holdings in shares of Integra LifeSciences by 413.8% during the 1st quarter. CWM LLC now owns 6,664 shares of the life sciences company's stock worth $147,000 after acquiring an additional 5,367 shares during the period. Institutional investors own 84.78% of the company's stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.